Quince Therapeutics, Inc. (QNCX) Stock

Quince Therapeutics, Inc. (QNCX) is a Healthcare stock trading at $33.26 (as of 2026-08-21), with a market capitalization of $33.82M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Quince Therapeutics, Inc. is a biopharmaceutical company developing precision therapeutics for debilitating and rare diseases using a bone-targeting platform designed to deliver small molecules, peptides, or large molecules to the site of bone fracture and disease. Its lead candidate, NOV004, is an anabolic peptide engineered to concentrate at bone fracture sites.

Understand Quince Therapeutics, Inc.: how it makes money

Quince Therapeutics develops precision, bone-targeted biopharmaceutical drug candidates for debilitating and rare diseases, including its lead compound NOV004, and the provided information does not specify how the company generates revenue.

Quince Therapeutics is built around a bone-targeting drug platform, with its lead program NOV004 as the focal point, so future economics depend heavily on whether this precision targeting platform can translate into successful development outcomes for its therapies.

Business quality (Weak): Limited company data is provided here, with no reportable segments and no operating KPIs available, and revenue appears missing or shown as 0.0B for the latest quarter, which constrains a detailed profit-model read.

Valuation: At 1× earnings, QNCX trades 96% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

  • Precision bone-targeting platform: The company has discovered a broad bone-targeting drug platform designed to deliver small molecules, peptides, or large molecules directly to bone fracture and disease sites.
  • Lead compound centered on targeting: NOV004 is described as an anabolic peptide engineered to precisely target and concentrate at the bone fracture site.

Bear case

  • Execution risk tied to the drug development pipeline: Because the company’s approach is defined by its precision therapeutics platform and the lead compound NOV004, progress depends on development outcomes that are not detailed in the provided facts.
  • Loss-making operating profile in the latest quarter provided: For 2026-03-31, the dataset shows operating_margin_pct of -9118.8%, indicating losses, but it does not provide supporting operating metrics or segment detail.
Valuation — source: SEC EDGAR (first-party)
Price$33.26
Market Cap$33.82M
Price / Sales26.61
FCF Yield-139.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.24M
Net Margin-6750.7%
Revenue Growth (YoY)87.8%
EPS Growth (YoY)3520.6%
FCF Growth (YoY)63.7%
Financial Health — source: SEC EDGAR
Altman Z-Score15.98 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderNantahala Capital Management, LLC ($8.95M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODirk Thye
Employees36
CountryUS
IPO Date2019-05-09

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • eXoZymes, Inc. (EXOZ)
  • Instil Bio, Inc. (TIL)
  • Metagenomi, Inc. Common Stock (MGX)
  • Aligos Therapeutics, Inc. (ALGS)
  • Elutia Inc. (ELUT)
  • Jasper Therapeutics, Inc. (JSPR)
  • Dyadic International, Inc. (DYAI)
  • CEL-SCI Corporation (CVM)
QNCX earnings history · QNCX institutional & insider holders · QNCX KPIs & operating metrics · QNCX financials · QNCX investor presentations & press releases · QNCX SEC filings · QNCX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.